In addition, Tasocitinib was also shown to be effective in inhibition of JAK3 and STAT5 activation in peripheral blood mononuclear cells isolated from T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis [54]. This evidence concerns the gene JAK3 and T-cell leukemia.